REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Aug 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-20

Reporting Person: Fenimore Christopher R. (SVP Controller)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-20	Common Stock	M	13500	$179.13	Acquired	32520	Direct
2021-08-23	Common Stock	S	4576	$655.0	Disposed	27944	Direct
2021-08-23	Common Stock	S	9	$659.33	Disposed	27935	Direct
2021-08-23	Common Stock	S	23	$660.33	Disposed	27912	Direct
2021-08-23	Common Stock	S	88	$661.89	Disposed	27824	Direct
2021-08-23	Common Stock	S	1	$662.78	Disposed	27823	Direct
2021-08-23	Common Stock	S	70	$663.05	Disposed	27753	Direct
2021-08-23	Common Stock	S	14	$665.21	Disposed	27739	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-20	Non-Qualified Stock Option (right to buy)	$179.13	M	13500	Disposed	2022-12-14	Common Stock (13500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2082	Indirect
Common Stock	1459	Indirect
Common Stock	1897	Indirect
Common Stock	1861	Indirect
Common Stock	25	Indirect
Common Stock	25	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 9 shares of Company stock on August 23, 2021 at prices ranging from $659.28 to $659.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

F3: Represents volume-weighted average price of sales of 23 shares of Company stock on August 23, 2021 at prices ranging from $660.09 to $660.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

F4: Represents volume-weighted average price of sales of 88 shares of Company stock on August 23, 2021 at prices ranging from $661.47 to $661.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

F5: Represents volume-weighted average price of sales of 70 shares of Company stock on August 23, 2021 at prices ranging from $663.00 to $663.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 23, 2021 at each separate price.

F6: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.

F7: The stock option award vests in four equal annual installments, commencing one year after the date of grant.